TRIT1

Across TCGA pan-cancer cohorts, TRIT1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TRIT1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where TRIT1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TRIT1 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

LSCC, LUAD, and PDAC are the cancer types where TRIT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.497	<.001	8	view →
LUAD	All	III,IV	+0.427	<.001	7	view →
PDAC	Female	All	−0.596	.002	3	view →
CCRCC	Male	All	−0.148	<.001	3	view →
OV	All	All	−0.400	.031	2	view →
COAD	Male	All	+0.394	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TRIT1–LSCC

Open the LSCC breakdown →